Stock Analysis on Net
Stock Analysis on Net

Merck & Co. Inc. (NYSE:MRK)

$24.99

Cash Flow Statement
Quarterly Data

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Paying user area

Try for free

Merck & Co. Inc. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Merck & Co. Inc., consolidated cash flow statement (quarterly data)

US$ in millions

Microsoft Excel
3 months ended: Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Net income (loss) from continuing operations
Amortization
Depreciation
Depreciation and amortization (legacy)
Intangible asset impairment charges
(Income) loss from investments in equity securities, net
Charge for the acquisition of Eyebiotech Limited
Charge for the acquisition of MK-1045 (formerly CN201) from Curon Pharmaceutical
Charge for the acquisition of Harpoon Therapeutics, Inc.
Charge for the acquisition of Prometheus Biosciences, Inc.
Charge for the acquisition of Imago BioSciences, Inc.
Charge for the acquisition of Pandion Therapeutics, Inc.
Charge for the acquisition of VelosBio Inc.
Charge for acquisition of Peloton Therapeutics, Inc.
Deferred income taxes
Share-based compensation
Other
Net changes in assets and liabilities
Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities
Net cash provided by operating activities
Capital expenditures
Purchase of Seagen Inc. common stock
Purchases of securities and other investments
Proceeds from sale of Seagen Inc. common stock
Proceeds from sales of securities and other investments
Acquisition of Eyebiotech Limited, net of cash acquired
Acquisition of Elanco Animal Health Incorporated aqua business
Acquisition of Harpoon Therapeutics, Inc., net of cash acquired
Acquisition of MK-1045 (formerly CN201) from Curon Pharmaceutical
Acquisition of Prometheus Biosciences, Inc., net of cash acquired
Acquisition of Imago BioSciences, Inc., net of cash acquired
Acquisition of Acceleron Pharma Inc., net of cash acquired
Acquisition of Pandion Therapeutics, Inc., net of cash acquired
Acquisition of VelosBio Inc., net of cash acquired
Acquisition of ArQule, Inc., net of cash acquired
Acquisition of Antelliq Corporation, net of cash acquired
Acquisition of Peloton Therapeutics, Inc., net of cash acquired
Other acquisitions, net of cash acquired
Other
Net cash (used in) provided by investing activities
Net change in short-term borrowings
Proceeds from issuance of debt
Payments on debt
Dividends paid to stockholders
Distribution from Organon & Co.
Purchases of treasury stock
Proceeds from exercise of stock options
Other
Net cash provided by (used in) financing activities
Net cash provided by operating activities
Net cash used in investing activities
Net cash used in financing activities
Net cash flows provided by discontinued operations
Effect of exchange rate changes on cash, cash equivalents and restricted cash
Net increase (decrease) in cash, cash equivalents and restricted cash

Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Cash flow statement item Description The company
Net cash provided by operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Merck & Co. Inc. net cash provided by operating activities increased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.
Net cash (used in) provided by investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Merck & Co. Inc. net cash (used in) provided by investing activities increased from Q1 2024 to Q2 2024 but then decreased significantly from Q2 2024 to Q3 2024.
Net cash provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Merck & Co. Inc. net cash provided by (used in) financing activities increased from Q1 2024 to Q2 2024 but then slightly decreased from Q2 2024 to Q3 2024 not reaching Q1 2024 level.